(Adnkronos) - “Mirikizumab è il primo farmaco anti subunità p19 di IL-23, approvato per il trattamento, negli adulti della colite ulcerosa moderata a grave. E’ il primo farmaco”, di questa nuova classe, “che può essere utilizzato per questa tipologia di pazienti”. Lo ha detto Alessandro Armuzzi, responsabile Uo Ibd Humanitas di Rozzano (Mi) e professore di Gastroenterologia dell'Humanitas university, partecipando all’incontro con la stampa organizzato Lilly su ‘Colite ulcerosa: dai bisogni dei pazienti a nuove prospettive”.
Category
🗞
NewsTranscript
00:00Colitis ulcerosa is a chronic inflammatory bowel disease, together with Crohn's disease.
00:10It is estimated that in Italy there are more than 160,000 affected patients and more than
00:174,000 new diagnoses per year.
00:20It usually occurs in the youth, from 15 to 30 years old.
00:25The most common symptoms are rectal bleeding, diarrhea, fatigue, abdominal pain.
00:33The emergency evacuation is very important because it greatly impacts the quality of life of the patients.
00:39Once the symptoms have been reported, the patient goes to the doctor, who performs the main
00:44blood tests and feces tests, such as fecal calprotectin, and if there is an indication,
00:49a colonoscopy is performed with biopsies, which allows the diagnosis of colitis ulcerosa.
00:54Mirichizumab is the first anti-subunit P19 drug of Interleukin-23, which has been approved
01:01for the treatment of moderate to severe colitis ulcerosa.
01:05It is the first drug of the class that we can use to manage this type of patients.
01:13It is an innovative drug because it acts on the differentiation of lymphocytes T.
01:18It acts quickly and effectively, especially by intervening on those symptoms, such as
01:28diarrhea, blood, as well as many other drugs, but also the emergency evacuation, which greatly impacts
01:33the quality of life of the patients, with an excellent safety profile.
01:37It is a drug that can be used both in the first line of advanced therapies, after the failure
01:45or intolerance to traditional therapies, and also in the second line.
01:50In my opinion, it is better to use it first.
01:54Either in the first line, in those subjects where it is allowed to be used, for example
01:59fragile subjects, given the effectiveness and safety profile, or in the second line,
02:05perhaps after the failure of a similar biopsy, it is probably one of the best positions
02:12on which it would be necessary to start the treatment of a patient affected by colitis ulcerosa.